Rituximab significantly improves complete response rate in patients with primary CNS lymphoma
Journal of Neuro-Oncology, 05/14/2012
Birnbaum T et al. – The results indicate that rituximab might be efficacious in the treatment of primary CNS lymphoma (PCNSL) and support addition of this drug to current treatment protocols until data from randomized controlled trials becomes available. Immunochemotherapy with methotrexate (MTX) and ifosfamide (IFO), and rituximab seems to have excellent activity as induction chemotherapy and should be further tested in prospective trials.